Aplastic Anemia in Pregnancy

Aplastic anemia [AA] is a rare and life-threatening hematologic disorder characterized by pancytopenia and bone marrow failure.First documented in 1888 by Paul Ehrlich, AA has since been a subject of interest, especially its rare presentation during pregnancy.Pregnancy-associated aplastic anemia (p-AA) remains a scarce and challenging condition, with an incidence higher in Asian regions than in Western countries.The pathophysiology of AA is multifactorial, involving immune-mediated destruction of hematopoietic stem cells, often triggered by drugs, environmental toxins, or infections.Hormonal and immunological changes during pregnancy can worsen symptoms, although the exact mechanisms are not well understood.Diagnosing primary autoimmune aplastic anemia (p-AA) is challenging due to the physiological changes in blood during pregnancy, often requiring a bone marrow biopsy for confirmation.Complications for the mother, such as hemorrhage and infections, along with risks for the fetus, including preterm birth, highlight the seriousness of this condition.Current treatment approaches focus on supportive care, including blood transfusions, while immunosuppressive therapies like cyclosporine can provide additional benefits in some instances.Bone marrow transplantation can be curative, but it is contraindicated during pregnancy due to significant risks to the fetus.Given the rarity and complexity of AA in pregnancy, there is a need for a better understanding of the current state of knowledge and best practices in managing this challenging condition, involving multidisciplinary teams with hematologists, obstetricians, and anesthesiologists to optimize outcomes.